Literatura ACTA MEDICINAE 5–7/2025 Gynekologie | Onkogynekologie | Urologie

2 Léčba pokročilého cervikálního karcinomu kombinací s pembrolizumabem – kazuistika
prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň

2 HPV test ve screeningu karcinomu děložního hrdla
MUDr. Lukáš Dostálek, Ph.D. Onkogynekologické centrum, Klinika gynekologie, porodnictví a neonatologie, 1. LF UK a VFN v Praze

2 Benefit z udržovací terapie olaparibem ve druhé linii
MUDr. Anna Nohejlová Medková Onkologická klinika, 2. LF UK a FN v Motole, Praha

2 Karcinom prostaty – nejčastější zhoubný nádor u mužů
MUDr. Jana Katolická, Ph.D. | MUDr. Lucia Tomková, Ph.D. Onkologicko-chirurgické oddělení, Fakultní nemocnice u svaté Anny v Brně

2 Papilární karcinom štítné žlázy v graviditě – kazuistika
MUDr. Hana Novotná Krajská nemocnice T. Bati Zlín, a. s., Thyrea ambulance, s. r. o.

3 Soudobá moderní terapeutika v gynekologické onkologii – zaměřeno na imunoterapii a cílenou léčbu – přehledové sdělení
MUDr. Monika Náležinská Klinika operační onkologie, oddělení gynekologické onkologie, MOÚ a LF MU, Brno

3 Serózní tubární intraepiteliální karcinomy (STIC) – management nálezu
MUDr. Michal Felsinger, Ph.D. | MUDr. Dita Münzová | MUDr. Jitka Hausnerová | doc. MUDr. Luboš Minář, Ph.D. Gynekologicko-porodnická klinika, Onkogynekologické centrum, LF MU a FN Brno

3 Umělá inteligence a digitalizace cytologických vyšetření ve screeningu karcinomu děložního hrdla
MUDr. Iva Kinkorová Luňáčková, MIAC Bioptická laboratoř, s. r. o., Plzeň

3 Farmakologická léčba hyperaktivního močového měchýře a urgentní inkontinence
MUDr. Lukáš Holub, Ph.D. Urologická klinika, LF UK a FN Hradec Králové

4 Vliv hyperaktivního močového měchýře na kvalitu života
MUDr. Olga Szabová Urogynekologické centrum, Gynekologicko-porodnická klinika, FN Ostrava a LF Ostravské univerzity, Ostrava

4 Infekce močového měchýře
MUDr. Lukáš Holub, Ph.D. Urologická klinika, LF UK a FN Hradec Králové

5 Současné možnosti léčby vazomotorických symptomů v klimakteriu a postmenopauze
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha; 3. LF UK, Praha; IPVZ, Praha

5 Moderní přístupy k léčbě osteoporózy; současné možnosti farmakologické léčby
MUDr. Zdeněk Fojtík, Ph.D., Diagnosticko-terapeutické centrum, revmatologická ambulance, FN Brno a LF MU, Brno

6 Očkování v těhotenství
prof. MUDr. Petr Pazdiora, CSc. Ústav epidemiologie, LF UK v Plzni

6 Aktuální postupy indukce porodu
MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha; 3. LF UK, Praha; IPVZ, Praha

7 Imunologie a imunopatologie lidské reprodukce
Ing. Andrea Kestlerová | MUDr. Jindřich Madar, CSc. AREPIM, s. r. o. (Ambulance reprodukční imunologie), Praha

7 Vliv věku ženy na plodnost
MUDr. Kristýna Frühaufová Gynem IVF Centrum, Praha

7 Novodobý trend – social freezing
MUDr. Renáta Krmíčková, Ph.D. Next Fertility IVF Prof. Zech a ÚAR GPK FN Plzeň

Léčba pokročilého cervikálního karcinomu kombinací s pembrolizumabem – kazuistika

prof. MUDr. Jindřich Fínek, Ph.D., MHA Onkologická a radioterapeutická klinika, FN a LF UK, Plzeň

1 **Colombo, N. – Dubot, C. – Lorusso, D., et al.**: Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. *N Engl J Med*, 2021, 385, s. 1856–1867.

2 **Monk, B. J., et al.**: KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. Prezentováno na ASCO Annual Meeting, 2023.

HPV test ve screeningu karcinomu děložního hrdla

MUDr. Lukáš Dostálek, Ph.D. Onkogynekologické centrum, Klinika gynekologie, porodnictví a neonatologie, 1. LF UK a VFN v Praze

1 **Kitchener, H. C. – Castle, P. E. – Cox, J. T.**: Chapter 7: Achievements and limitations of cervical cytology screening. *Vaccine*, 2006, 24, suppl. 3, s. S3/63–70.

2 **Krejčí, D. – Mužík, J. – Šnábl, I., et al.**: Portál epidemiologie novotvarů v ČR [online]. Masarykova univerzita, Brno, 2024, www.svod.cz, verze 8.0.1.

3 **Hejduk, K. – Mandelová, L. – Ngo, O., et al.**: Národní screeningové centrum ÚZIS ČR. Praha, Ministerstvo zdravotnictví ČR a Ústav zdravotnických informací a statistiky ČR, 2024, www.nsc.uzis.cz.

4 **Damiani, G. – Federico, B. – Basso, D., et al.**: Socioeconomic disparities in the uptake of breast and cervical cancer screening in Italy: a cross sectional study. *BMC Public Health*, 2012, 12, s. 99.

5 Screening karcinomu děložního hrdla od 1. 1. 2024 – VZP ČR. Dostupné z: https://www.vzp.cz/poskytovatele/informace-pro-praxi/vykazovani-a-uhrady/screening-karcinomu-delozniho-hrdla, vyhledáno 9. 3. 2025.

6 **Koliopoulos, G. – Arbyn, M. – Martin-Hirsch, P., et al.**: Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. *Gynecol Oncol*, 2007, 104 s. 232–246.

7 **Woodman, C. B. J. – Collins, S. I. – Young, L. S.**: The natural history of cervical HPV infection: unresolved issues. *Nat Rev Cancer*, 2007, 7, s. 11–22.

8 **Strang, T. H. R. – Gottschlich, A. – Cook, D. A., et al.**: Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. *Am J Obstet Gynecol*, 2021, 225, s. 511.e1–511.e7.

9 **Ngo, O. – Chloupková, R. – Cibula, D., et al.**: Direct mailing of HPV self-sampling kits to women aged 50-65 non-participating in cervical screening in the Czech Republic. *Eur J Public Health*, 2024, 34, s. 361–367.

Benefit z udržovací terapie olaparibem ve druhé linii

MUDr. Anna Nohejlová Medková Onkologická klinika, 2. LF UK a FN v Motole, Praha

1 **Banerjee, S. – Moore, K. N. – Colombo, N., et al.**: Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2021, 22, s. 1721–1731.

2 **Zváriková, M.**: Cílená léčba nově diagnostikovaného a relabujícího epiteliálního ovariálního karinomu – aktualizovaná doporučení ESMO. *Farmakoterapie*, 2021, 17, s. 981–986.

3 **González-Martín, A. – Pothuri, B. – Vergote, I., et al.**: Niraparib in patients with newly diagnosed advanced ovarian cancer. *N Engl J Med*, 2019, 381, s. 2391–2402.

4 **Pujade-Lauraine, E., et. al.**: Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*, 2017, 18, s. 1274–1284.

Karcinom prostaty – nejčastější zhoubný nádor u mužů

MUDr. Jana Katolická, Ph.D. | MUDr. Lucia Tomková, Ph.D. Onkologicko-chirurgické oddělení, Fakultní nemocnice u svaté Anny v Brně

1 www.uzis.cz

2 **Vale, C. L. – Fisher, D. J. – Godolphin, P. J., et al.**: Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials. *Lancet Oncol*, 2023, 24, s. 783.

3 **Hoyle, A. P. – Ali, A. – James, N. D., et al.**: Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. *Eur Urol*, 2019, 76, s. 719.

4 **Sathianathen, N. J. – Koschel, S. – Thangasamy, I. A., et al.**: Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. *Eur Urol*, 2020, 77, s. 365.

5 **Hussain, M. – Tombal, B. – Saad, F., et al.**: Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. *J Clin Oncol*, 2023, 41, s. 3595.

6 **Loriot, Y., et al.**: Management of non-metastatic castrate-resistant prostate cancer: a systematic review. *Cancer Treat Rev*, 2018, 70, s. 223–231.

7 **Fallah, J. – Zhang, L. – Amatya, A., et al.**: Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. *Lancet Oncol*, 2021, 22, s. 1230.

8 **Ruiz de Porras, V. – Font, A. – Aytes, S.**: Chemotherapy in metastatic castration-resistant prostate cancer: current scenario and future perspectives. *Cancer Lett*, 2021, 523, s. 162–169.

9 **Parker, C. – Nilsson, S. – Heinrich, D., et al.**: Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*, 2013, 369, s. 213.

10 **Garje, R. – Rumble, R. B. – Parikh, R. A.**: Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO Rapid Recommendation. *J Clin Oncol*, 2022, 40, s. 3664.

11 **Nizialek, E. – Antonarakis, E. S.**: PARP inhibitors in metastatic prostate cancer: evidence to date. *Cancer Management and Research*, 2020, 12, s. 8105–8114.

12 www.uptodate.com

13 Populační program časného záchytu karcinomu prostaty. 2023. Dostupné z: https://mzd.gov.cz/populacni-pilotni-program-casneho-zachytu-karcinomu-prostaty/, vyhledáno 7. 3. 2025.

14 **Scher, H. I., et al.**: Trial design and objectives for castration-resistant prostate cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. *J Clin Oncol*, 2016, 34, s. 1402–1418.

15 **Mottet, N. – Van den Bergh, R. C. N. – Van den Broeck., et al.**: *EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent*. 2021, 79, s. 243–262.

16 **Cornford. P. – Van den Bergh, R. C. N. – Briers, E., et al.**: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*, 2024, 86, s. 148–163.

17 **Sweeney, C. J. – Chen, Y.-H. – Carduci, M., et al.**: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med*, 2015, 373, s. 737–746.

18 **Fizazi, K., et al.**: Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. *N Engl J Med*, 2017, 377, s. 352–360.

19 **Chi, K. N. – Agarwal, N. – Bjaetell, A., et al.**: Apalutamide for metastatic, castration-sensitive prostate cancer. *N Engl J Med*, 2019, 381, s. 13–24.

20 **Armstrong, A. J. – Szmulewitz, R. Z. – Petrylak, D. P., et al.**: ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. *J Clin Oncol*, 2019, 37, s. 2974–2986.

21 **Davis, I. D. – Martin, A. J. – Strockler, M. R., et al.**: Enzalutamide with standard first-line therapy in metastatic prostate cancer. *N Engl J Med*, 2019, 381, s. 121–131.

22 **James, N. D. – Tannock, I. – N'Dow, J., et al.**: The Lancet Commission on prostate cancer: planning for the surge in cases. *Lancet*, 2016 387, s. 116–177.

Papilární karcinom štítné žlázy v graviditě – kazuistika

MUDr. Hana Novotná Krajská nemocnice T. Bati Zlín, a. s., Thyrea ambulance, s. r. o.

1 **de Escobar, M. – Escobar, F.**: Maternal thyroid hormones early in pregnancy and fetal brain development. *Best Pract Res Clin Endocrinol Metab*, 2004, 18, s. 225–248.

2 **Potluková, E. – Jiskra, J. – Telička, Z., et al.**: Pozitivita protilátek proti tyreoidální peroxidáze u eutyreózních těhotných žen jako rizikový faktor pozdějšího rozvoje dystyreózy. *Diabetologie Metabolismus Endokrinologie Vyziva*, 2011, 14, s. 27–32.

3 **De Groot, L. – Abalovich, M. – Alexander, E. K., et al.**: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*, 2012, 97, s. 2543–2565.

4 **Alexander, E. K. – Pearce, E. N. – Brent, G. A., et al.**: Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*, 2017, 27, s. 315–389.

5 **Limanová, Z. – Jiskra, J. – Springer, D., et al.**: Doporučení pro diagnostiku a léčbu onemocnění štítné žlázy v těhotenství a pro ženy s poruchou fertility. *Prakt Gyn*, 2013, 17, s. 173–199.

6 **Špitálníková, S. – Horáček, J. – Antonín, P., et al.**: Výskyt tyreopatií v neselektované populaci těhotných žen jednoho regionu a význam rizikových faktorů pro jejich vznik. *Diabetes, Metabolismus, Endokrinologie, Vyziva*, 2011, 14, s. 60–64.

7 NSC. Časný záchyt tyreopatií v těhotenství 2019–2022. Dostupné z: https://nsc.uzis.cz/projekt/26-casny-zachyt-tyreopatie-tehotenstvi/, vyhledáno 7. 5. 2025.

8 **Zamrazil, V. – Bilek, R. – Cerovska, J., et al.**: The elimination of iodine deficiency in the Czech Republic: the steps toward success. *Thyroid*, 2004, 14, s. 49–56.

9 **Pătrașcu, A. I. – Pătrașcu, A. – Dobre, A., et al.**: Thyroid cancer and pregnancy: a systematic ten-year-review. *Medicina*, 2023, 59, 1989.

10 **Guo, L – Zhang, Y. – Zhang, L., et al.**: Pregnancy outcomes after thyroid cancer: a retrospective cohort study. *J Clin Endocrinol Metab*, 2020, 105.

11 **Kloos, R. T.**: Management of differentiated thyroid cancer in pregnancy. *Thyroid*, 2011, 21, s. 763–770.
12 **Stagnaro-Green, A. – Abalovich, M. – Alexander, E., et al.**: Guidelines for the management of thyroid nodules and cancer during pregnancy. *Thyroid*, 2011, 21, s. 1081–1125.
13 **Papaleontiou, M. – Haymart, M. R.**: Thyroid nodules and cancer during pregnancy, post-partum and preconception planning: Addressing the uncertainties and challenges. *Best Pract Res Clin Endocrinol Metab*, 2020, 34, 101363.

Soudobá moderní terapeutika v gynekologické onkologii – zaměřeno na imunoterapii a cílenou léčbu – přehledové sdělení

MUDr. Monika Náležinská Klinika operační onkologie, oddělení gynekologické onkologie, MOÚ a LF MU, Brno

1 **Vokurka, S. – Hugo, J.**: *Moderní molekuly v onkologii*. Maxdorf, 2019.
2 **Náležinská, M. – Anderson, C. K. – Garrett, A. P., et al.**: Imunoonkoterapie u pacientek s onkogynekologickými nádory. *Onkol Rev*, 2023, 10, s. 178–188.
3 **Náležinská, M. – Chovanec, J.**: Imunoterapie v léčbě dospělých pacientek s rekurentním nebo pokročilým karcinomem endometria. *Onkol Rev*, 2024, 11, s. 306–312.
4 **Náležinská, M. – Chovanec, J.**: PARP inhibitory v léčbě pokročilého, metastatického nebo recidivujícího karcinomu endometria. *Onkologie*, 2024, 18, s. 305–310.
5 **Fínek, J. – Zikán, M.**: *Karcinom ovaria*. Framakon Press, 2023.
6 **Kolářová, H. – Náležinská, M. – Chovanec, J.**: Imunoterapie v léčbě pokročilých a recidivujících stadií karcinomu děložního hrdla. *Onkologie*, 2024, 18, s. 315–317.
7 Modrá kniha, Linkos. Dostupné z: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/, vyhledáno 1. 4. 2025.

Serózní tubární intraepiteliální karcinomy (STIC) – management nálezu

MUDr. Michal Felsinger, Ph.D. | MUDr. Dita Münzová | MUDr. Jitka Hausnerová | doc. MUDr. Luboš Minář, Ph.D.
Gynekologicko-porodnická klinika, Onkogynekologické centrum, LF MU a FN Brno

1 **Presl, J. – Bouda, J. – Vlasák, P.**: Hereditární riziko ovariálního karcinomu a profylaktická opatření. *Actual Gyn*, 2018, 10, s. 14–18.
2 **Colombi, I. – D'Indinosante, M. – Lazzeri, L., et al.**: Tubal cancer clinical management: two exceptional scenarios and a review of the literature. *J Clin Med*, 2024, 13, s. 5075.
3 **Weinberger, V. – Bednarikova, M. – Cibula, D., et al.**: Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. *Expert Rev Anticancer Ther*, 2016, 16, s. 1311–1321.
4 **Luvero, D. – Angioli, R. – Notaro, E., et al.**: Serous tubal intraepithelial carcinoma (STIC): a review of the Literature on the Incidence at the time of prophylactic surgery. *Diagnostics*, 2024, 14, s. 2577.
5 **Cheng, Z. – Ennis, D. P. – Lu, B., et al.**: The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions. *J Pathol*, 2024, 264, s. 42–54.
6 **Stewart, K. T. – Hoang, L. – Kwon, J. S.**: Serous tubal intraepithelial carcinoma (STIC) outcomes in an average risk population. *Gynecol Oncol Rep*, 2024, 51, 101334.
7 **Van Den Berg, C. B. – Dasgupta, S. – Ewing-Graham, P. C., et al.**: Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. *Gynecol Oncol*, 2024, 187, s. 113–119.
8 **Van Der Ven, J. – Linz, V. C. – Anic, K., et al.**: A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany. *Arch Gynecol Obstet*, 2023, 308, s. 527–534.
9 **Negri, S. – Fisch, C. – De Hullu, J. A., et al.**: Diagnosis and management of isolated serous tubal intraepithelial carcinoma: A qualitative focus group study. *BJOG Int J Obstet Gynaecol*, 2024, 131, s. 1851–1861.

Umělá inteligence a digitalizace cytologických vyšetření ve screeningu karcinomu děložního hrdla

MUDr. Iva Kinkorová Luňáčková, MIAC Bioptická laboratoř, s. r. o., Plzeň

1 **Nanda, K. – McCrory, D. C. – Myers, E. R., et al.**: Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Ann Intern Med*, 2000, 132, s. 809–819.
2 **Singh, D. – Vignat, J. – Lorenzoni, V., et al.**: Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. *Lancet Glob Health*, 2023, 11, s. e197–e206.
3 **Nayar, R. – Wilbur, D. C.**: The Pap test and Bethesda 2014. *Cancer Cytopathol*, 2015, 123, s. 271–281.
4 **Thrall, M. J.**: Automated screening of Papanicolaou tests: A review of the literature. *Diagn Cytopathol*, 2019, 47, s. 20–27.
5 **Lozano, R.**: Comparison of computer-assisted and manual screening of cervical cytology. *Gynecol Oncol*, 2007, 104, s. 134–138.
6 **Miller, F. S. – Nagel, L. E. – Kenny-Moynihan, M. B.**: Implementaion of the ThinPrep imaging system in a high-volume metropolitan laboratory. *Diagn Cytopathol*, 2007, 35, s. 213–217.
7 **Capitanio, A. – Dina, R. E. – Treanor, D.**: Digital cytology: a short review of technical and methodological approaches and applications. *Cytopathology*, 2018, 29, s. 317–325.
8 **Lew, M. – Wilbur, D. C. – Pantanowitz, L.**: Computational cytology: lessons learned from Pap test computer-assisted screening. *Acta Cytol*, 2021, 65, s. 286–300.
9 **Cantley, R. L. – Jing, X. – Smola, B., et al.**: Validation of AI-assisted ThinPrep Pap test screening using the Genius™ Digital Diagnostics System. *Pathol Inform*, 2024,15, 100391.
10 Genius™ Digital Diagnostics System Instructions for Use. AW-30074-001 Rev. 002 1-2024. Hologic. 2024, s. 1–34, www.hologic.com.
11 **Ikenberg, H. – Lieder,S. – Ahr, A., et al.**: Comparison of the Hologic Genius Digital Diagnostic System with the ThinPrep Imaging System – A retrospective assessment. *Cancer Cytopathol*, 2023, 7, s. 424–432.
12 **Pantanowitz, L. – Harrington, S.**: Experience reviewing digital Pap test using gallery of images. *J Pathol Inform*, 2021, 12, s. 7.

Farmakologická léčba hyperaktivního močového měchýře a urgentní inkontinence

MUDr. Lukáš Holub, Ph.D. Urologická klinika, LF UK a FN Hradec Králové

1 The overactive bladder: from basic science to clinical management consensus conference. Proceedings, Londýn, Anglie, 29. 6. 1997. *Urology*, 1997, 50, suppl. 6A, s. 1–114.
2 **Wein, A. J. – Rackley, R. R.**: Overactive bladder: a better understanding of pathophysiology, diagnosis and management. *J Urol*, 2006, 175, s. S5–S10.
3 **Morrison, J. – Steers, W. D. – Brading, A. F., et al.**: Neurophysiology and neuropharmacology. Dostupné z: https://www.ics.org/publications/ici_2/chapters/Chap02.pdf, vyhledáno 25. 3. 2025.
4 **McKeage, K.**: Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. *Clin Drug Investig*, 2013, 33, s. 71–91.
5 **Zinner, N. R.**: Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder. *Expert Opin Pharmacother*, 2005, 6, s. 1409–1420.
6 **Herschorn, S. – Swift, S. – Guan, Z., et al.**: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int*, 2010, 105, s. 58–66.
7 **Cardozo, L. – Amarenco, G. – Pushkar, D., et al.**; SUNRISE study group: Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). *BJU Int*, 2013, 111, s. 804–810.
8 **Herschorn, S. – Swift, S. – Guan, Z., et al.**: Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. *BJU Int*, 2010, 105, s. 58–66.
9 **Zinner, N. – Susset, J. – Gittelman, M., et al.**: Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. *Int J Clin Pract*, 2006, 60, s. 119–126.
10 **Chapple, C. R. – Kaplan, S. A. – Mitcheson, D., et al.**: Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. *Eur Urol*, 2013, 63, s. 296–305.
11 **Staskin, D. – Frankel, J. – Varano, S., et al.**: International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR. *J Urol*, 2020, 204, s. 316–324.
12 **Hunsballe, J. M. – Djurhuus, J. C.**: Clinical options for imipramine in the management of urinary incontinence. *Urol Res*, 2001, 29, s. 118–125.
13 **Araklitis. G. – Baines, G. – da Silva, A. S., et al.**: Recent advances in managing overactive bladder. *F1000 Res*, 2020, 9, F1000 Faculty Rev-1125.
14 **Biehl, C. – Plotsker, O. – Mirkin, S.**: A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. *Menopause*, 2019, 26, s. 431–453.
15 **Marcelissen, T. A. – Rahnama'i, M. S. – Snijkers, A., et al.**: Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. *World J Urol*, 2017, 35, s. 307–311.
16 **Nambiar, A. K. – Arlandis, S. – Bø, K., et al.**: European Association of Urology guidelines on the diagnosis and management of female non-neurogenic lower urinary tract symptoms. Part 1: Diagnostics, overactive bladder, stress urinary incontinence, and mixed urinary incontinence. *Eur Urol*, 2022, 82, s. 49–59.

Vliv hyperaktivního močového měchýře na kvalitu života

MUDr. Olga Szabová Urogynekologické centrum, Gynekologicko-porodnická klinika, FN Ostrava a LF Ostravské univerzity, Ostrava

1 **Abrams, P. – Cardozo, L. – Fall, M., et al.**: Standardisation Sub-Committee of the International Continence Society: The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. *Urology*, 2003, 61, s. 37–49.

2 **Irwin, D. E. – Milsom, I. – Hunskaar, S., et al.**: Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. *Eur Urol*, 2006, 50, s. 1306–1314; diskuze s. 1314–1315.

3 **Zhang, L. – Cai, N. – Mo, L., et al.**: Global prevalence of overactive bladder: a systematic review and meta-analysis. *Int Urogynecol J*, 2025, https://doi.org/10.1007/s00192-024-06029-2.

4 **Naumann, G. – Hitschold, T. – Frohnmeyer, D., et al.**: Sexual disorders in women with overactive bladder and urinary stress incontinence compared to controls: a prospective study. *Geburtshilfe Frauenheilkd*, 2021, 81, s. 1039–1046.

5 **Bartoli, S. – Aguzzi, G. – Tarricone, R.**: Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. *Urology*, 2010, 75, s. 491–500.

6 **Hilmer, S. N. – Gnjidic, D.**: The anticholinergic burden: from research to practice. *Aust Prescr*, 2022, 45, s. 118–120.

7 **Nitti, V. W. – Khullar, V. – van Kerrebroeck, P., et al.**: Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. *Int J Clin Pract*, 2013, 67, s. 619–632.

8 **Wang, Ch.-Ch. – Jiang, Y.-H. – Kuo, H.-Ch.**: Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB. *Low Urin Tract Symptoms*, 2019, 11, s. O180–O185.

9 **Yeowell, G. – Smith, P. – Nazir, J., et al.**: Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. *BMJ Open*, 2018, 8, e021889.

10 **Chancellor, M. B. – Migliaccio-Walle, K., et al.**: Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. *Clin Ther*, 2013, 35, s. 1744–1751.

11 **Liao, Ch.-H. – Kuo, H.-Ch.**: High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment. *Medicine*, 2016, 95, e4962.

Infekce močového měchýře

MUDr. Lukáš Holub, Ph.D. Urologická klinika, LF UK a FN Hradec Králové

1 **Cunha, C. B. (ed.)**: *Schlossberg's Clinical Infectious Disease*. Oxford University Press, 2022, s. 423–429.

2 **Gupta, K. – Hooton, T. M. – Naber, K. G., et al.**: International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis*, 2011, 52, s. e103–120.

3 **Wagenlehner, F. M. – Schmiemann, G. – Hoyme, U., et al.**: National S3 guideline on uncomplicated urinary tract infection: recommendations for treatment and management of uncomplicated community-acquired bacterial urinary tract infections in adult patients. *Urologe A*, 2011, 50, s. 153–169.

4 **Abrahamian, F. M. – Moran, G. J. – Talan, D. A.**: Urinary tract infections in the emergency department. *Infect Dis Clin North Am*, 2008, 22, s. 73–87, vi.

5 **Little, P. – Turner, S. – Rumsby, K., et al.**: Dipsticks and diagnostic algorithms in urinary tract infection: development and validation, randomised trial, economic analysis, observational cohort and qualitative study. *Health Technol Assess*, 2009, 13, s. iii–iv, ix–xi, 1–73.

6 **Lane, D. R. – Takhar, S. S.**: Diagnosis and management of urinary tract infection and pyelonephritis. *Emerg Med Clin North Am*, 2011, 29, s. 539–552.

7 **Czaja, C. A. – Stamm, W. E. – Stapleton, A. E., et al.**: Prospective cohort study of microbial and inflammatory events immediately preceding Escherichia coli recurrent urinary tract infection in women. *J Infect Dis*, 2009, 200, s. 528–536.

8 **Adeghate, J. – Juhász, E. – Pongrácz, J., et al.**: Does Staphylococcus saprophyticus cause acute cystitis only in young females, or is there more to the story? A one-year comprehensive study done in Budapest, Hungary. *Acta Microbiol Immunol Hung*, 2016, 63, s. 57–67.

9 **Kanj, S. S. – Kanafani, Z. A.**: Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. *Mayo Clin Proc*, 2011, 86, s. 250–259.

10 **Hooton, T. M. – Bradley, S. F. – Cardenas, D. D., et al.**: Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. *Clin Infect Dis*, 2010, 50, s. 625–663.

11 **Tiemstra, J. D. – Chico, P. D. – Pela, E.**: Genitourinary infections after a routine pelvic exam. *J Am Board Fam Med*, 2011, 24, s. 296–303.

12 **Hsiao, C. J. – Cherry, D. K. – Beatty, P. C., et al.**: National ambulatory medical care survey: 2007 summary. *Natl Health Stat Report*, 2010, s. 1–32.

13 **Naber, K. G. – Schito, G. – Botto, H., et al.**: Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. *Eur Urol*, 2008, 54, s. 1164–1175.

14 **Little, P. – Merriman, R. – Turner, S., et al.**: Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. *BMJ*, 2010, 340, b5633.

15 **Molander, U. – Arvidsson, L. – Milsom, I., et al.**: A longitudinal cohort study of elderly women with urinary tract infections. *Maturitas*, 2000, 34, s. 127–131.

16 **Johnson, L. – Sabel, A. – Burman, W. J., et al.**: Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates. *Am J Med*, 2008, 121, s. 876–884.

17 American College of Obstetricians and Gynecologists (ACOG). 2008. Treatment of urinary tract infections in nonpregnant women. Dostupné z: https://guideline.gov/content.aspx?id=12628, vyhledáno 22. 9. 2010..

18 **Falcone, M. – Suardi, L. R. – Tiseo, G., et al.**: Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). *JAC Antimicrob Resist*, 2022, 4, dlac064.

19 **Corcione, S. – Montrucchio, G. – Shbaklo, N., et al.**: First cases of Candida auris in a referral intensive care unit in Piedmont region, Italy. *Microorganisms*, 2022, 10, 1521.

20 **Taylor, R. A. – Moore, C. L. – Cheung, K. H., et al.**: Predicting urinary tract infections in the emergency department with machine learning. *PLoS One*, 2018, 13, e0194085.

21 **Barclay, L.**: Urinary tract infection: 3 questions aid diagnosis in women. *Medscape Medical News*, 2013. Dostupné z: https://www.medscape.com/viewarticle/810667?form=fpf, vyhledáno 5. 5. 2025.

22 **Knottnerus, B. J. – Geerlings, S. E. – Moll van Charante, E. P., et al.**: Toward a simple diagnostic index for acute uncomplicated urinary tract infections. *Ann Fam Med*, 2013, 11, s. 442–451.

23 **Schaeffer, A. J. – Schaeffer, E. M.**: Infections of the urinary tract. In: McDougal, W. S. – Wein, A. J. – Kavoussi, L. R., et al. (eds.): *Campbell-Walsh Urology*. Philadelphia, PA: Elsevier Saunders, 2012, s. 46–55.

24 **Lifshitz, E. – Kramer, L.**: Outpatient urine culture: does collection technique matter?. *Arch Intern Med*, 2000, 160, s. 2537–2540.

25 **Propp, D. A. – Weber, D. – Ciesla, M. L.**: Reliability of a urine dipstick in emergency department patients. *Ann Emerg Med*, 1989, 18, s. 560–563.

26 **Mehnert-Kay, S. A.**: Diagnosis and management of uncomplicated urinary tract infections. *Am Family Physician*, 2005, 27, s. 1–9.

27 **Gould, C. V. – Umscheid, C. A. – Agarwal, R. K., et al.**: Guideline for prevention of catheter-associated urinary tract infections 2009. *Infect Control Hosp Epidemiol*, 2010, 31, s. 319–326.

28 **Kauffman, C. A. – Fisher, J. F. – Sobel, J. D., et al.**: Candida urinary tract infections-diagnosis. *Clin Infect Dis*, 2011, 52, suppl. 6, s. S452–S456.

29 **Falagas, M. E. – Kotsantis, I. K. – Vouloumanou, E. K., et al.**: Antibiotics versus placebo in the treatment of women with uncomplicated cystitis: a meta-analysis of randomized controlled trials. *J Infect*, 2009, 58, s. 91–102.

30 **Foxman, B.**: The epidemiology of urinary tract infection. *Nat Rev Urol*, 2010, 7, s. 653–660.

31 **Little, P. – Moore, M. V. – Turner, S., et al.**: Effectiveness of five different approaches in management of urinary tract infection: randomised controlled trial. *BMJ*, 2010, 340, c199.

32 **Lavigne, J. P. – Bruyère, F. – Bernard, L., et al.**: Resistance and virulence potential of uropathogenic Escherichia coli strains isolated from patients hospitalized in urology departments: a French prospective multicentre study. *J Med Microbiol*, 2016, 65, s. 530–537.

33 **Christiaens, T. C. – De Meyere, M. – Verschraegen, G., et al.**: Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. *Br J Gen Pract*, 2002, 52, s. 729–734.

34 **Bleidorn, J. – Gágyor, I. – Kochen, M. M., et al.**: Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract infection? Results of a randomized controlled pilot trial. *BMC Med*, 2010, 8, 30.

35 **Grigoryan, L. – Zoorob, R. – Wang, H., et al.**: Low concordance with guidelines for treatment of acute cystitis in primary care. *Open Forum Infect Dis*, 2015, 2, ofv159.

36 **Sigler, M. – Leal, J. E. – Bliven, K., et al.**: Assessment of appropriate antibiotic prescribing for urinary tract infections in an internal medicine clinic. *South Med J*, 2015, 108, s. 300–304.

37 **Olson, R. P. – Harrell, L. J. – Kaye, K. S.**: Antibiotic resistance in urinary isolates of Escherichia coli from college women with urinary tract infections. *Antimicrob Agents Chemother*, 2009, 53, s. 1285–1286.

38 **McKinnell, J. A. – Stollenwerk, N. S. – Jung, C. W., et al.**: Nitrofurantoin compares favorably to recommended agents as empirical treatment of uncomplicated urinary tract infections in a decision and cost analysis. *Mayo Clin Proc*, 2011, 86, s. 480–488.

39 **Falagas, M. E. – Vouloumanou, E. K. – Togias, A. G., et al.**: Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. *J Antimicrob Chemother*, 2010, 65, s. 1862–1877.

40 **Xin, H. – Rosario-Colon, J. A. – Eberle, K.**: Novel intravenous immunoglobulin therapy for the prevention and treatment of Candida auris and Candida albicans disseminated candidiasis. *mSphere*, 2023, e0058422.

41 **Nicolle, L. E. – Bradley, S. – Colgan, R., et al.**: Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis*, 2005, 40, s. 643–654.

42 **Dalal, S. – Nicolle, L. – Marrs, C. F., et al.**: Long-term Escherichia coli asymptomatic bacteriuria among women with diabetes mellitus. *Clin Infect Dis*, 2009, 49, s. 491–497.

43 **Beerepoot, M. A. – ter Riet, G. – Nys, S., et al.**: Cranberries vs antibiotics to prevent urinary tract infections: a randomized double-blind noninferiority trial in premenopausal women. *Arch Intern Med*, 2011, 171, s. 1270–1278.

44 **Jepson, R. G. – Craig, J. C.**: Cranberries for preventing urinary tract infections. *Cochrane Database Syst Rev*, 2008, CD001321.

45 **Tempera, G. – Corsello, S. – Genovese, C., et al.**: Inhibitory activity of cranberry extract on the bacterial adhesiveness in the urine of women: an ex-vivo study. *Int J Immunopathol Pharmacol*, 2010, 23, s. 611–618.

46 **Frellick, M.**: Drinking more water reduces repeat urinary tract infections. *Medscape Medical News*. Dostupné z: https://www.medscape.com/viewarticle/886775?form=fpf, vyhledáno 5. 5. 2025.

47 **De Vita, D. – Giordano, S.**: Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. *Int Urogynecol J*, 2012, 23, s. 1707–1713.

48 **Hanuš, M., et al.**: Imunostimulace polybakteriálním lyzátem (Urivac) v prevenci recidivujících infekcí dolních močových cest. *Česká urologie*, 2015, 19, s. 33–43.

Současné možnosti léčby vazomotorických symptomů v klimakteriu a postmenopauze

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha; 3. LF UK, Praha; IPVZ, Praha

1 **Sharma, G.**: The menopause transition and women's health at midlife. *Int J Obstet Gynaecol Nurs*, 2020, 2, s. 9–13, doi: 10.33545/26642298.2020.v2.i2a.34.
2 **Hooper, S. – Marshallm, V. – Becker, C., et al.**: Mental health and quality of life in postmenopausal women as a function of retrospective menopause symptom severity. *Menopause*, 2022, 29, s. 707–713.
3 **Whiteley, J. – da Costa DiBonaventura, M. – Wagner, J. S., et al.**: The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. *J Womens Health*, 2013, 22, s. 983–990.
4 **Gallicchio, L. – Miller, S. – Zacur, H., et al.**: Hot flashes and blood pressure in midlife women. *Maturitas*, 2010, 65, s. 69–74.
5 **Freeman, E. – Sammel, M. – Sanders, R.**: Risk of long-term hot flashes after natural menopause. *Menopause*, 2014, 21, s. 924–932.
6 **Choi, H. – Chang, Y. – Kim, Y., et al.**: Vasomotor and other menopause symptoms and the prevalence of ideal cardiovascular health metrics among premenopausal stage women. *Menopause*, 2023, 30, s. 750–757.
7 **Szmuilowicz, E. – Manson, J. – Rossouw, J., et al.**: Vasomotor symptoms and cardiovascular events in postmenopausal women. *Menopause*, 2011, 18, s. 603–610.
8 **Kim, M. – Seo, S. – Chae, H., et al.**: Perceptions of postmenopausal symptoms and treatment options among middle-aged Korean women. *Yonsei Med J*, 2017, 58, s. 533.
9 **Gallicchio, L. – Miller, S. – Kiefer, J., et al.**: Risk factors for hot flashes among women undergoing the menopausal transition. *Menopause*, 2015, 22, s. 1098–1107.
10 **Hoikkala, H. – Haapalahti, P. – Viitasalo, M., et al.**: Association between vasomotor hot flashes and heart rate variability in recently postmenopausal women. *Menopause*, 2010, 17, s. 315–320.
11 **de Villiers, T. J. – Gass, M. L. S. – Haines, C. J. E., et al.**: Global consensus statement on menopausal hormone therapy. *Climacteric*, 2013, 16, s. 203–204.
12 **Stuenkel, C. – Davis, S. – Gompel, A., et al.**: Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*, 2015, 100, s. 3975–4011.
13 **Joffe, H. – Massler, A. – Sharkey, K.**: Evaluation and management of sleep disturbance during the menopause transition. *Semin Reprod Med*, 2010, 28, s. 404–421.
14 **Li, Y. – Chang, J. – Shi, G., et al.**: Effects of stellate ganglion block on perimenopausal hot flashes: a randomized controlled trial. *Front Endocrinol*, 2023, 14, 1293358.
15 **Cintrón, D. – Lipford, M. – Larrea-Mantilla, L., et al.**: Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. *Endocrine*, 2016, 55, s. 702–711.
16 **Van Schoor, J.**: Hot flushes. *South African Family Practice*, 2015, 57, s. 4.
17 **Freedman, R.**: Treatment of menopausal hot flashes with 5-hydroxytryptophan. *Maturitas*, 2010, 65, s. 383–385.
18 **Brown, J. N. – Wright, B. R.**: Use of gabapentin in patients experiencing hot flashes. *Pharmacotherapy*, 2009, 29, s. 74–81.
19 **Butt, D. – Lock, M. – Lewis, J., et al.**: Gabapentin for the treatment of menopausal hot flashes. *Menopause*, 2008, 15, s. 310–318.
20 **Johns, C. – Seav, S. M. – Dominick, S. A., et al.**: Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. *Breast Cancer Res Treat*, 2016, 156, s. 415–426.
21 **Hubing, K. – Wingo, J. – Brothers, R., et al.**: Nitric oxide synthase inhibition attenuates cutaneous vasodilation during postmenopausal hot flash episodes. *Menopause*, 2010, 17, s. 978–982.
22 **Muñiz, V. – Padilla, V. – Alldredge, C., et al.**: Clinical hypnosis and cognitive behavioral therapy for hot flashes: a scoping review. *Women's Health Reports*, 2025, 6, s. 1–20.
23 **Elkins, G. – Fisher, W. – Johnson, A., et al.**: Clinical hypnosis in the treatment of postmenopausal hot flashes. *Menopause*, 2013, 20, s. 291–298.
24 **Zhou, J. – Qu, F. – Xi-sheng, S., et al.**: Acupuncture and auricular acupressure in relieving menopausal hot flashes of bilaterally ovariectomized chinese women: a randomized controlled trial. *Evid Based Complement Alternat Med*, 2011, 2011, 713274.
25 **Luoto, R. – Moilanen, J. – Heinonen, R., et al.**: Effect of aerobic training on hot flushes and quality of life – a randomized controlled trial. *Ann Med*, 2012, 44, s. 616–626.
26 **Yadav, A. – Verma, M. – Sharma, A., et al.**: Fezolinetant: a non-hormonal NK3R antagonist for the treatment of hot flushes and vasomotor symptoms. *Dermatol Rev*, 2024, doi.org/10.1002/der2.70009.
27 **Neal-Perry, G. – Cano, A. – Lederman, S., et al.**: Safety of fezolinetant for vasomotor symptoms associated with menopause. *Obstet Gynecol*, 2023, 141, s. 737–747.
28 **Onge, E. – Phillips, B. – Miller, L.**: Fezolinetant: a new nonhormonal treatment for vasomotor symptoms. *J Pharm Technol*, 2023, 39, s. 291–297.
29 **Cano, A. – Nappi, R. – Santoro, N., et al.**: Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. *BJOG*, 2024, 131, s. 1296–1305.
30 **Morga, A. – Ajmera, M. – Gao, E., et al.**: Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. *Menopause*, 2023, 31, s. 68–76.
31 **Santoro, N. – Waldbaum, A. – Lederman, S., et al.**: Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). *Menopause*, 2020, 27, s. 1350–1356.
32 **Santoro, N. – Nappi, R. – Neal-Perry, G., et al.**: Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studis (SKYLIGHT 1 and 2). *Menopause*, 2024, 31, s. 247–257.
33 **Qi, Y. – Ming, F. – Ma, J., et al.**: Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial. *J Int Med Res*, 2024, 52, 03000605241246624.
34 **Ruan, X. – Bai, W. – Ren, M., et al.**: Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in east Asia: a phase 3 randomized study (MOONLIGHT I). *J Int Med Res*, 2024, 52.
35 **Li, Y.**: An open-label, single and multiple dose study to evaluate the pharmacokinetics and safety of fezolinetant in healthy Chinese female subjects. *Drug Des Devel Ther*, 2025, 19, s. 2243–2252.

Moderní přístupy k léčbě osteoporózy; současné možnosti farmakologické léčby

MUDr. Zdeněk Fojtík, Ph.D., Diagnosticko-terapeutické centrum, revmatologická ambulance, FN Brno a LF MU, Brno

1 FRAX Fracture Risk Assessment Tool; nástroj pro výpočet. Dostupné z: https://frax.shef.ac.uk/FRAX/tool.aspx?lang=cz, vyhledáno 15. 3. 2025.
2 **Harvey, N. C. – Biver, E. – Kaufman, J. M., et al.**: The role of calcium supplementation in healthy musculoskeletal ageing: An Experts consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundation for Osteoporosis (IOF). *Osteoporos Int*, 2017, 28, s. 447–462.
3 **Pérez-López, F. R. – Chedraui, P. – Pilz, S.**: Vitamin D supplementation after the menopause. *Ther Adv Endocrinol Metab*, 2020, 11, s. 1–13.
4 **Cashman, K. D. – Dowling, K. G. – Skrabakova, Z., et al.**: Vitamin D deficiency in Europe: pandemic? *Am J Clin Nutr*, 2016, 103, s. 1033–1044.
5 **Gallagher, J. C. – Sai, A. – Templin, T., et al.**: Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. *Ann Inter Med*, 2012, 156, s. 425–437.
6 **Lips, P., et al.**: Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. *Eur J Endocrinol*, 2019, 180, s. P23–P54.
7 **Kanis, J. A. – Cooper, C. – Rizzoli, R., et al.**: European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int*, 2019, 30, s. 3–44.
8 **Anderson, G. L.**; The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA*, 2004, 291, s. 1701–1712.
9 **Cauley, J. A. – Robbins, J. – Chen, Z., et al.**: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA*, 2003, 290, s. 1729–1738.
10 **Seeman, E. – Crans, G. G. – ez-Perez, A., et al.**: Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. *Osteoporos Int*, 2006, 17, s. 313–316.
11 **Black, D. M. – Cummings, S. R. – Karpf, D. B., et al.**: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. *Lancet*, 1996, 348, s. 1535–1541.
12 **Cummings, S. R. – Black, D. M. – Thompson, D. E., et al.**: Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *JAMA*, 1998, 280, s. 2077–2082.
13 **Black, D. M. – Delmas, P. D. – Eastell, R., et al.**: HORIZON Pivotal Fracture Trial: once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med*, 2007, 356, s. 1809–1822.
14 **Händel, M. N. – Cardoso, I. – von Bülow, C., et al.**: Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network metaanalysis, and meta-regression analysis of randomised clinical trials. *BMJ*, 2023, 381, e068033.
15 **Khan, A. A. – Morrison, A. – Hanley, D.A.**: Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*, 2015, 30, s. 3–23.
16 **Ayers, Ch. – Kansagara, D. – Lazur, B., et al.**: Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network metaanalysis for the American College of Physicians. *Ann Intern Med*, 2023, 176, s. 182–195.
17 **Shane, E. – Burr, D., et al.**: Atypical subtrochanteric and diaphyseal femoral fractures: a second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*, 2014, 29, s. 1–23.
18 **Meier, R. P. H. – Perneger, T. V. – Stern, R., et al.**: Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. *Arch Intern Med*, 2012, 172, s. 930–936.
19 **Schilcher, J. – Michaëlsson, K. – Aspenberg, P.**: Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med*, 2011, 364, s. 1728–1737.
20 **O'Donnell, S. – Cranney, A. – Wells, G. A., et al.**: Strontium ranelate for preventing and treating postmenopausal osteoporosis. *Cochrane Database Syst Rev*, 2006, CD005326.
21 **Cummings, S. R. – San Martin, J. – McClung, M. R., et al.**: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med*, 2009, 361, s. 756–765.
22 **Papapoulos, S., et al.**: Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. *J Bone Miner Res*, 2012, 27, s. 694–701.
23 **Cosman, F. – Crittenden, D. B. – Adachi, J. D., et al.**: Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med*, 2016, 375, s. 1532–1543.
24 **Neer, R. M. – Arnaud, C. D. – Zanchetta, J. R., et al.**: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med*, 2001, 344, s. 1434–1441.
25 **Andrews, E. B. – Gilsenan, A. W. – Midkiff, K.,et al.**: The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. *J Bone Miner Res*, 2012, 27, s. 2429–2437.
26 **Miller, P. D. – Hattersley, G. – Riis, B. J., et al.**; ACTIVE Study Investigators: Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. *JAMA*, 2016, 316, s. 722–733.
27 **Saag, K. G. – Petersen, J. – Brandi, M. L., et al.**: Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med*, 2017, 377, s. 1417–1427.
28 EVENITY, preskripční informace dostupné z: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf, vyhledáno 15. 3. 2025.
29 **Leder, B. Z.**: Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. *JBMR Plus*, 2018, 2, s. 62–68.
30 **Black, D. M. – Bilezikian, J. P. – Ensrud, K. E., et al.**; PaTH study investigators: One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med*, 2005, 353, s. 555–565.
31 **Ensrud, K. E. – Schousboe, J. T.**: Anabolic therapy for osteoporosis. *JAMA*, 2021, 326, s. 350–351.
32 **Cosman, F. – Oates, M. – Betah, D., et al.**: Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. *J Bone Miner Res*, 2024, 39, s. 1268–1277.
33 **Ayers, C. H. – Kansagara, D. – Lazur, B., et al.**: Effectiveness and safety of treatments to prevent fractures in people with low bone mass or primary osteoporosis: a living systematic review and network metaanalysis for the American College of Physicians. *Ann Intern Med*,2023, 176, s. 182–195.

Očkování v těhotenství

prof. MUDr. Petr Pazdiora, CSc. Ústav epidemiologie, LF UK v Plzni

1 **Khan, T. – Malik, S. – Rafeekh, L., et al.**: Facilitators and barriers to maternal immunization and strategies to improve uptake in low-income and lower-middle income countries: A systematic review. *Hum Vaccin Immunother*, 2024, 20, 2411823.

2 **Rick, A. M. – Beigi, R.**: The Maternal immunizations: Past, present, and future. *Clin Obstet Gynecol*, 2024, 67, s. 605–619.

3 **Sebghati, M. – Khalil, A.**: Uptake of vaccination in pregnancy. *Best Pract Res Clin Obstet Gynaecol*, 2021, 76, s. 53–65.

4 **Álvarez Aldeán, J. – Álvarez García, J. F. – de la Calle Fernández-Miranda M., et al.**: Vaccination in pregnancy. Consensus document of the CAV-AEP and the SEGO. *An Pediatr*, 2024, 100, s. 268–274.

5 Doporučení České vakcinologické společnosti pro očkování v těhotenství, 9. 12. 2024. Dostupné z: https://www.vakcinace.eu/doporuceni-a-stanoviska/doporuceni-ceske-vakcinologicke-spolecnosti-pro-ockovani-v-tehotenstvi, vyhledáno 27. 3. 2025.

6 Guidelines for Vaccinating Pregnant Persons. 2024. Dostupné z: https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html, vyhledáno 27. 3. 2025.

7 **Makan-Murphy, N. – Madhi, S. A. – Dangor, Z.**: Safety, efficacy, and effectiveness of maternal vaccination against respiratory infections in young infants. *Semin Respir Crit Care Med*, 2024, doi: 10.1055/a-2471-6906.

8 **Blanchard-Rohner, G. – Eberhardt, C.**: Review of maternal immunisation during pregnancy: focus on pertussis and influenza. *Swiss Med Wkly*, 2017, 147, w14526.

9 **Kelly, S. M. – Bracken, O. – Bholah, T., et al.**: Uptake rates and attitudes to influenza and COVID-19 vaccination in pregnancy – a prospective cohort study. *Ir J Med Sci*, 2024, 193, s. 289–293.

10 **Fell, D. B. – Savitz, D. A. – Kramer, M. S., et al.**: Maternal influenza and birth outcomes: systematic review of comparative studies. *BJOG*, 2017, 124, s. 48–59.

11 **Frawley, J. E. – He, W. Q. – McCallum, L., et al.**: Birth outcomes after pertussis and influenza diagnosed in pregnancy: A retrospective, population-based study. *BJOG*, 2025, 132, s. 355–364.

12 **Meijer, W. J. – van Noortwijk, A. G. – Bruinse, H. W., et al.**: Influenza virus infection in pregnancy: a review. *Acta Obstet Gynecol Scand*, 2015, 94, s. 797–819.

13 **Engjom, H. M. – Skår, F. – Meijerink, H., et al.**: Pertussis vaccine – pregnant women are the target group in the childhood vaccination programme. *Tidsskr Nor Laegeforen*, 2024, 144.

14 European Centre for Disease Prevention and Control. In: *Increase of pertussis cases in the EU/EEA, 2024*. Stockholm, ECDC, 2024.

15 European Centre for Disease Prevention and Control. Pertussis. In: *ECDC. Annual epidemiological report for 2017*. Stockholm, ECDC, 2019.

16 European Centre for Disease Prevention and Control. Pertussis. In: *ECDC. Annual epidemiological report for 2022*. Stockholm, ECDC, 2024.

17 **Merdrignac, L. – Aït El Belghiti, F. – Pandolfi, E., et al.**: Incidence and severity of pertussis hospitalisations in infants aged less than 1 year in 37 hospitals of six EU/EEA countries, results of PERTINENT sentinel pilot surveillance systém. December 2015 to December 2018. *Euro Surveill*, 2021, 26, 1900762.

18 Informační systém infekčních nemocí: Dostupné z: https://ereg.ksrzis.cz/Registr/ISIN/Statistika?dgFiltr=1, vyhledáno 27. 3. 2025.

19 **Karasek, D. – Baer, R. J. – McLemore, M. R., et al.**: The association of COVID-19 infection in pregnancy with preterm birth: A retrospective cohort study in California. *Lancet Reg Health Am*, 2021, 2, 100027.

20 **Raffetti, E. – Bolton, T. – Nolan, J., et al.**: CVD-COVID-UK/COVID-IMPACT Consortium and the longitudinal health and wellbeing COVID-19 national core study. COVID-19 diagnosis, vaccination during pregnancy, and adverse pregnancy outcomes of 865,654 women in England and Wales: a population-based cohort study. *Lancet Reg Health Eur*, 2024, 45, 101037.

21 **Villar, J. – Ariff, S. – Gunier, R. B., et al.**: Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: The INTERCOVID multinational cohort study. *JAMA Pediatr*, 2021, 175, s. 817–826.

22 **Günther, J. – Ziert, Y. – Andresen, K., et al.**: Variability in COVID-19 symptom presentation during pregnancy and its impact on maternal and infant outcomes across the pandemic. *Int J Infect Dis*, 2024, 146, 107157.

23 **Kenmoe, S. – Chu, H. Y. – Dawood, F. S., et al.**: Burden of respiratory syncytial virus–associated acute respiratory infections during pregnancy. *J Infect Dis*, 2024, 229, s. 51–60.

24 **Li, Y. – Wang, X. – Blau, D. M., et al.**: Respiratory virus global epidemiology network; RESCEU investigators: Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. *Lancet*, 2022, 399, s. 2047–2064.

25 **Pazdiora, P. – Šanca, O.**: Infekce respiračním syncytiálním virem (RSV) u dětí v prvním roce života (Česká republika, 2017–2022). *Epidemiol Mikrobiol Imunol*, 2024, 73, s. 67–75.

26 **Reeves, R. M. – Hardelid, P. – Panagiotopoulos, N., et al.**: Burden of hospital admissions caused by respiratory syncytial virus (RSV) in infants in England: A data linkage modelling study. *J Infect*, 2019, 78, s. 468–475.

27 **Pazdiora, P. – Šanca, O. – Dušek, L.**: Hospitalizace a úmrtí na infekci RSV v České republice v roce 2023. *Vakcinologie*, 2024, 18, s. 162–168.

28 **Pazdiora, P. – Jelínková, H. – Kozerovský, M., et al.**: Očkování v těhotenství – studie v porodnicích Plzeňského kraje. *Epidemiol Mikrobiol Imunol*. V tisku.

29 **Liptáková, M. – Košťálová, J. – Kynčl, J., et al.**: Monitoring the vaccination of pregnant women against pertussis – single-centre one-year study in the Czech Republic. *Bratisl Lek Listy*, 2023, 124, s. 285–291.

30 World Health Organisation. Influenza vaccines: WHO position paper. online. 2020. Dostupné z: https://www.who.int/ wer/2005/wer8033.pdf?ua¼1, vyhledáno 27. 3. 2025.

31 **Ferrari, A. – Moretti, G. – Corazza, I., et al.**: Pregnancy vaccination predictive factors and uptake profiles among Italian women: A cross-sectional survey study on a large population. *Int J Gynaecol Obstet*, 2023, 162, s. 105–115.

32 **Razzaghi, H. – Kahn, K. E. – Calhoun, K., et al.**: Influenza, Tdap, and COVID-19 vaccination coverage and hesitancy among pregnant women – United States. April 2023. *MMWR Morb Mortal Wkly Rep*, 2023, 72, s. 1065–1071.

33 **Widdershoven, V. – Reijs, R. P. – Eskes, A., et al.**: Acceptance of vaccination against pertussis, COVID-19 and influenza during pregnancy: a cross-sectional study. *BMC Pregnancy Childbirth*, 2023, 23, s. 219.

34 European Centre for Disease Prevention and Control: *Survey report on national seasonal influenza vaccination recommendations and coverage rates in EU/EEA countries*. Stockholm, ECDC, 2024.

35 **Kynčl, J. – Liptáková, M. – Košťálová, J., et al.**: Vaccination against influenza in pregnant women in a maternity hospital in the Czech Republic in the season 2020–2021. *BMC Public Health*, 2023, 23, s. 1029.

36 **Corbeau, M. – Mulliez, A. – Chenaf, C., et al.**: Trends of influenza vaccination coverage in pregnant women: a ten-year analysis from a french healthcare database. *Sci Rep*, 2022, 12, s. 1–9.

37 Národní zdravotnický informační portál, www.nzip.cz.

38 Očkování proti onemocnění covid-19 u těhotných a kojících žen, konsenzuální stanovisko České vakcinologické společnosti a České gynekologické a porodnické společnosti ČLS JEP, 3. 6. 2021. Dostupné z: https://www.vakcinace.eu/doporuceni-a-stanoviska/ockovani-proti-onemocneni-covid-19-u-tehotnych-a-kojicich-zen, vyhledáno 27. 3. 2025.

39 **Pazdiora. P.**: Očkování v těhotenství (přednáška). XXIX. pracovní setkání gynekologů, Plzeň. 7. 12. 2024. Dostupné z: https://www.eu-gaoffice.org/congresses/17th-annual-congress-2024/, vyhledáno 27. 3. 2025.

40 European Commission. State of vaccine confidence in the EU 2018. Dostupné z: https://health.ec.europa.eu/system/files/2018-11/2018_vaccine_confi¬dence_en_0.pdf, vyhledáno 27. 3. 2025.

41 Národní zdravotnický informační portál: Denní reporting pro COVID-19 a chřipku v ČR. Dostupné z: https://www.nzip.cz/data/2101-covid-19-chripka-denni-reporting-datovy-souhrn, vyhledáno 27. 3. 2025.

42 Státní ústav pro kontrolu léčiv. Dostupné z: https://opendata.sukl.cz/?q=katalog/dis-13, vyhledáno 27. 3. 2025.

43 Centers for Disease Control and Prevention: Weekly RSV vaccination dashboard, 2025. Dostupné z: https://www.cdc.gov/rsvvaxview/data/index.html, vyhledáno 27. 3. 2025.

44 **Kemp, M. – Capriola, A. – Schauer, S.**: RSV immunization uptake among infants and pregnant persons – Wisconsin. October 1, 2023-March 31, 2024. *Vaccine*, 2025, 47, 126674.

45 Public Health Scotland: Respiratory syncytial virus (RSV) pregnancy vaccination in Scotland. 28. 11. 2024. Dostupné z: https://scotland.shinyapps.io/phs-vaccination-surveillance/, vyhledáno 27. 3. 2025.

46 Public Health Wales: RSV vaccination report: November 2024. Dostupné z: https://phw.nhs.wales/topics/immunisation-and-vaccines/immunisation-surveillance/rsv-vaccination-report-november-2024-summarypdf-pdf/, vyhledáno 27. 3. 2025.

47 **Razai, M. S. – Mansour, R. – Ravindran, P., et al.**: Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review. *PLoS One*, 2024, 19, e0298407.

48 Ústav zdravotnických informací a statistiky ČR (2025). Průměrný věk rodiček v ČR dle kraje PZS v letech 2023 a 2024. Národní registr reprodukčního zdraví, modul Rodičky. Získáno na základě žádosti o data č. UZIS/002083/2025.

49 **Comparcini, D. – Cicolini, G. – Totaro, M., et al.**: Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study. *Hum Vaccin Immunother*, 2025, 21, 2450858.

50 Český statistický úřad: Velké srovnání regionů: Rozdíly ve mzdách jsou propastné. Uveřejněno 9. 3. 2025.

51 Ministerstvo vnitra ČR. Dostupné z: https://www.mvcr.cz/clanek/cizinci-s-povolenym-pobytem.aspx, vyhledáno 27. 3. 2025.

52 **Maertens, K. – Braeckman, T. – Blaizot, S., et al.**: Coverage of recommended vaccines during pregnancy in Flanders, Belgium. Fairly good but can we do better? *Vaccine*, 2018, 36, s. 2687–2693.

53 **Razai, M. S. – Hargreaves, S. – Oakeshott, P.**: Challenges and opportunities of vaccination during pregnancy: perspectives of 20 healthcare professionals. *J Public Health Policy*, 2025, doi: 10.1057/s41271-025-00548-y.

54 **Descamps, A. – Launay, O. – Bonnet, C., et al.**: Seasonal influenza vaccine uptake and vaccine refusal among pregnant women in France: results from a national survey. *Hum Vaccin Immunother*, 2020, 16, s. 1093–1100.

55 **Riad, A. – Jouzová, A. – Üstün, B., et al.**: COVID-19 vaccine acceptance of pregnant and lactating women (PLW) in Czechia: An analytical cross-sectional study. *Int J Environ Res Public Health*, 2021, 18, 13373.

Aktuální postupy indukce porodu

MUDr. Petr Křepelka, Ph.D. Ústav pro péči o matku a dítě, Praha; 3. LF UK, Praha; IPVZ, Praha

1 ACOG Practice Bulletin No. 107: Induction of labor. *Obstet Gynecol*, 2009,114, s. 386–397.

2 **Bigelow, C. A. – Khander, A. – Robles, B. N., et al.**: 137: Grand multiparity and great grand multiparity: obstetric risks in a contemporary cohort. *Am J Obstet Gynaecol Res*, 2019, 220, s. S105–S106.

3 **Gibson, K. S. – Waters, T. P.**: Measures of success: Prediction of successful labor induction. *Semin Perinatol*, 2015, 39, s. 475–482.

4 **Carmichael, S. L. – Snowden, J. M.**: The ARRIVE trial: interpretation from an epidemiologic perspective. *J Midwifery Womens Health*, 2019, 64, s. 657–663.

5 **Chen, H. Y. – Grobman, W. A. – Blackwell, S. C., et al.**: Neonatal and maternal adverse outcomes among low-risk parous women at 39-41 weeks of gestation. *Obstet Gynecol*, 2019, 134, s. 288–294.

6 **Hamm, R. – Srinivas, S. – Levine, L.**: Risk factors and racial disparities related to low maternal birth satisfaction with labor induction: a prospective, cohort study. *BMC Pregnancy and Childbirth*, 2019, 19.

7 **Nassar, N. – Schiff, M. – Roberts, C.**: Trends in the distribution of gestational age and contribution of planned births in new south wales, australia. *Plos One*, 2013, 8, e56238.

8 **Martin, J. A. – Osterman, M. J. – Sutton, P. D.**: Are preterm births on the decline in the United States? Recent data from the National Vital Statistics System. *NCHS Data Brief*, 2010, s. 1–8. PMID: 20604990.

9 Rodička a novorozenec 2016–2021. Zdravotnická statistika. Praha. ÚZIS ČR, 2023. Dostupné z: https://www.uzis.cz/res/f/008423/rodnov2016-2021.pdf, vyhledáno 5. 5. 2025.

10 **Casteleiro, A. – Santibanez, M. – Paras-Bravo, P., et al.**: Clinical practice outcomes and differential results in maternal and neonatal morbidity among pregnant women in Spain who are candidates for a normal birth: a cross-sectional study. *BMJ Open*, 2019, 9, e026899.

11 **Zhu, J. – Xue, L. – Shen, H., et al.**: Labor induction in China: a nationwide survey. *BMC Pregnancy and Childbirth*, 2022, 22, 463.

12 **Gerli, S. – Favilli, A. – Giordano, C., et al.**: Single indications of induction of labor with prostaglandins and risk of cesarean delivery: a retrospective cohort study. *J Obstet Gynaecol Res*, 2013, 39, s. 926–931.

13 **Arrowsmith, S. – Wray, S. – Quenby, S.**: Maternal obesity and labour complications following induction of labour in prolonged pregnancy. *BJOG*, 2011, 118, s. 578–588.

14 **Bueno, B. – San-Frutos, L. – Salazar, F., et al.**: Variables that predict the success of labor induction. *Acta Obstet Gynaecol Scand*, 2005, 84, s. 1093–1097.

15 **Wilkinson, C. – Bryce, R. – Adelson, P., et al.**: A randomised controlled trial of outpatient compared with inpatient cervical ripening with prostaglandin E_2 (OPRA study). *BJOG*, 2014, 122, s. 94–104.

16 **Kuper, S. – Jauk, V. – Baalbaki, S., et al.**: Does early artificial rupture of membranes speed labor in preterm inductions? *Am J Perinatol*, 2017, 35, s. 716–720.

17 **Cazorla, M. – Marques, A. – Sanmartín, J., et al.**: Effectiveness, safety and costs of labor induction with intravaginal misoprostol versus dinoprostone vaginal insert. *Clin Invest*, 2017, 7, s. 33–39.

18 **Datta, M. R. – Ghosh, M. D. – AyazAhmed Kharodiya, Z.**: Comparison of the efficacy and safety of sublingual versus oral misoprostol for the

induction of labor: a randomized open-label study. *Cureus*, 2023, 15, e49422.
19 **Arif, R. – Mazhar, T. – Jamil, M.**: Induction of labor in primigravid term pregnancy with misoprostol or dinoprostone: a comparative study. *Cureus*, 2019, 11, e5739.
20 **Das, D. – Medhi, R. – Chowdhury, N.**: Comparison between effectiveness of sublingual misoprostol and intracervical dinoprostone gel for induction of labour in pregnant women. *Int J Res Med Sciences*, 2023, 11, s. 2134–2139.
21 **Veena, B. – Samal, R. – Inbaraj, L., et al.**: Sublingual misoprostol (PGE1) versus intracervical dinoprostone (PGE2) gel for induction of labour: a randomized control trail. *J Obstet Gynaecol India*, 2015, 66, s. 122–128.
22 **Alfirevic, Z. – Keeney, E. – Dowswell, T., et al.**: Methods to induce labour: a systematic review, network meta-analysis and cost-effectiveness analysis. *BJOG*, 2016, 123, s. 1462–1470.
23 **Cazorla, M. – Marques, A. – Sanmartín, J., et al.**: Effectiveness, safety and costs of labor induction with intravaginal misoprostol versus dinoprostone vaginal insert. *Clin Invest*, 2017, 7.
24 **Halilzade, I. – Halilzade, M. I. – Sert, Ü. Y., et al.**: Can transvaginal cervical elastography predict the success of induction of labor with oxytocin? *Z Geburtshilfe Neonatol*, 2023, 227, s. 277–280.
25 **Msumi, R.**: Predictors for successful induction of labour at muhimbili national hospital. *AJMCRR*, 2023, 2.
26 **Firasy, A.**: The labor-induced pregnancy cases in Dr Soetomo General Hospital: a descriptive study. *Med Health Scienc J*, 2021, 5, s. 7–13.
27 **Beltran, J. – González, R.**: A prospective, single center study on clinical safety and efficacy of dinoprostone gel for cervical ripening in pregnant women not in labor. *J Med University Santo Tomas*, 2019, 3, doi: 10.35460/2546-1621.2018-0094
28 **Nguyen, T. – Huong, T. – Dung, T.**: Effective evaluation of labor induction by modifier double balloon Foley catheter at 108 Military Central Hospital. *J 108 Clin Med Pharm*, 2021, 16, doi: 10.52389/ydls.v16iTA.1110.
29 **Banotra, P. – Rashid, A.**: Pre-induction cervical ripening: a prospective and comparative study of intra-cervical Foley's catheter and prostaglandin E2 gel. *Int J Res Rev*, 2022, 9, s. 328–333.
30 **Özdemir, B. – Özdemir, H. – Atalay, C.**: The importance of fetal adrenal gland volume measurement in successful labor induction with oxytocin. *J Obst Gynaecol Res*, 2022, 48, s. 2514–2521.
31 **Lee, H. – Huang, B. – Cheng, M., et al.**: Intracervical foley catheter plus intravaginal misoprostol vs intravaginal misoprostol alone for cervical ripening: a meta-analysis. *Int J Environ Res Public Health*, 2020, 17, 1825.
32 **Ande, A. – Ezeanochie, M. – Olagbuji, N.**: Induction of labor in prolonged pregnancy with unfavorable cervix: comparison of sequential intracervical foley catheter–intravaginal misoprostol and intravaginal misoprostol alone. *Arch Gynecol Obstet*, 2011, 285, s. 967–971.
33 **Abdel Aziz, M. A, – Jahanfar, S. – Abedi, P., et al.**: Concurrent administration of oxytocin with Foley catheter versus Misoprostol for induction of labor: A systematic review and meta-analysis. 2020, doi: org/10.21203/rs.2.20722/v2.

Imunologie a imunopatologie lidské reprodukce

Ing. Andrea Kestlerová | MUDr. Jindřich Madar, CSc. AREPIM, s. r. o. (Ambulance reprodukční imunologie), Praha

1 **Madar, J. – Ulčová-Gallová, Z., et al.**: *Imunologie a imunopatologie lidské reprodukce. Vybrané kapitoly*. Mladá fronta, Praha, 2016.
2 **Ulčová-Gallová, Z. – Madar, J., et al.**: *Imunologie a imunopatologie lidské reprodukce*. Maxdorf, Praha, 2020.

Vliv věku ženy na plodnost

MUDr. Kristýna Frühaufová Gynem IVF Centrum, Praha

1 **Borges Cavalcante, M. – Martins Sampaio, O. G. – Câmara, F. E. A., et al.**: Ovaria aging in humans: potential strategies for extending reproductive lifespan. *Geroscience*, 2023, 45, s. 2121–2133.
2 **La Marca, A. – Spada, E. – Sighinolfi, G., et al.**: Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. *Fertil Steril*, 2011, 95, s. 684–688.
3 **Dewailly, D. – Andersen, C. Y. – Balnen, A., et al.**: The physiology and clinical utility of anti-Müllerian hormone in women. *Hum Reprod Update*, 2014, 1–16.
4 **Cimadomo, D. – Fabozzi, E. – Vaiarelli, A., et al.**: Impact of maternal age on oocyte and embryo competence. *Front Endocrinol*, 2018, 9, 327.
5 **Park, S. U. – Walsh, L. – Berkowitz,. K. M.**: Mechanisms of ovarian aging. *Reproduction*, 2021, 162, 19–R33.
6 **Homer, H. A.**: Understanding ovaria aging. *Minerva Obstetrics and Gynecology*, 2024, 76, s. 284–292.
7 **Tal, R. – Seifer, D. B.**: Ovarian reserve testing: a user's guide. *Am J Obstet Gynecol*, 2017, 217, s. 129–140.
8 **Morin, S. J. – Patounakis, G. – Juneau, C. R., et al.**: Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance. *Hum Reprod*, 2018, 33, s. 1489–1498.
9 **Chiang, T. – Duncan, F. E. – Schindler, K., et al.**: Evidence that weakened centromere cohesion is a leading cause of age-related aneuploidy in oocytes. *Current Biology*, 2010, 20, s. 1522–1528.
10 **Chiang, T. – Schultz, R. M. – Lampson, M. A.**: Age-dependent susceptibility of chromosome cohesion to premature separase activation in mouse oocytes. *Biol Reprod*, 2011, 85, s. 1279–1283.
11 **Kukarashi, H. – Tsutsumi, M. – Nishiyama, S., et al.**: Molecular basis of maternal age-related increase in oocyte aneuploidy. *Congenit Anom*, 2012, 52, s. 8–15.
12 **Venkatesan, S. – Khaw, A. K. – Hande, M. P.**: Telomere biology—insights into an intriguing phenomenon. *Cells*, 2017, 6, 15.
13 **Oldfield, A. L. – Kazemi, M. – Lujan, M. E.**: Impact of obesity on anti-Mullerian hormone (AMH) levels in women of reproductive age. *J Clin Med*, 2021, 10, 3192.
14 **Franasiak, J. M. – Forman, E. J. – Hong, K. H., et al.**: The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. *Fertil Steril*, 2014, 101, s. 656–663.

Novodobý trend – social freezing

MUDr. Renáta Krmíčková, Ph.D. Next Fertility IVF Prof. Zech a ÚAR GPK FN Plzeň

1 **Lockwood, G. M.**: Social egg freezing: the prospect of reproductive 'immortality' of dangerous delusion? *Reprod Biomed Online*, 2011, 23, s. 334–340.
2 **Brown, S.**: Europe's demographic crisis is over-unofficial. *Focus Reprod*, 2010, s. 28–31.
3 **Smallwood, S. – Jeffries, J.**: Family building intentions in England and Wales: trends, outcomes and interpretation. *Popul Trends*, 2003, s. 114.
4 **Doyle, J. O., et al.**: Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. *Fertil Steril*, 2016, 105, s. 459–466.
5 **Chen, C.**: Pregnancy after human oocyte cryopreservation. *Lancet*, 1986, 1, s. 884–886.